SomaGenics Secures NIH Funding
News Oct 05, 2016
SomaGenics has been awarded a $1.8M two-year NIH SBIR Phase II grant to further develop its RealSeq–AC technology for next-generation sequencing (NGS) of small RNAs such as microRNA.
Real-Seq®-AC dramatically reduces bias in small RNA sequencing libraries compared to commercially available library construction methods. “Bias reduction is critical for the discovery of previously undetected RNAs and enables a more accurate analysis of small RNA abundances,” according to Dr. Sergei Kazakov, VP of Discovery Research at SomaGenics and Principal Investigator on the NIH grant.
This Phase II award allows SomaGenics to further develop the RealSeq-AC library construction approach including streamlining the workflow, increasing library yield, and broadening its utility beyond sequencing microRNAs to include other RNA species such tRNAs, fragments of mRNAs and long noncoding RNAs (lncRNAs).
“This additional funding will allow us to continue expanding and optimizing the RealSeq platform, further strengthening SomaGenics’ suite of tools for small RNA discovery and validation. Besides RealSeq, these tools also include our proprietary RT-qPCR technologies miR-ID and miR-Direct, which can be used to validate potential biomarkers discovered through sequencing”, commented Dr. Brian Johnston, CEO of SomaGenics.
Potential Genetic Mechanism Behind Obesity IdentifiedNews
New research from the Research Triangle suggests that variants in a gene called ankyrin-B -- carried by millions of Americans -- could cause people to put on pounds through no fault of their own.
Attacking Telomeres Offers First Effective Glioblastoma TherapyNews
Blocking TRF1 – a telomere protector – interrupts tumour growth and increases survival in various mouse models of glioblastoma.READ MORE
Discovery of Reversible "Master Switch" Sheds Light on Regulation of Developmental GenesNews
The bivalent master switch model provides a conceptually simple explanation for how each developmental step is made along the path to different cell types, dependent on cell type-specific proteins, but acting through this common module.READ MORE